These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

582 related articles for article (PubMed ID: 38641067)

  • 1. Unity among the diverse RNA-guided CRISPR-Cas interference mechanisms.
    Ganguly C; Rostami S; Long K; Aribam SD; Rajan R
    J Biol Chem; 2024 Jun; 300(6):107295. PubMed ID: 38641067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The CRISPR-associated DNA-cleaving enzyme Cpf1 also processes precursor CRISPR RNA.
    Fonfara I; Richter H; Bratovič M; Le Rhun A; Charpentier E
    Nature; 2016 Apr; 532(7600):517-21. PubMed ID: 27096362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structures, mechanisms and applications of RNA-centric CRISPR-Cas13.
    Yang H; Patel DJ
    Nat Chem Biol; 2024 Jun; 20(6):673-688. PubMed ID: 38702571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Mechanisms of RNA Targeting by Cas13-containing Type VI CRISPR-Cas Systems.
    O'Connell MR
    J Mol Biol; 2019 Jan; 431(1):66-87. PubMed ID: 29940185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Approaches to study CRISPR RNA biogenesis and the key players involved.
    Behler J; Hess WR
    Methods; 2020 Feb; 172():12-26. PubMed ID: 31325492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural Variation of Type I-F CRISPR RNA Guided DNA Surveillance.
    Pausch P; Müller-Esparza H; Gleditzsch D; Altegoer F; Randau L; Bange G
    Mol Cell; 2017 Aug; 67(4):622-632.e4. PubMed ID: 28781236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular insights into DNA interference by CRISPR-associated nuclease-helicase Cas3.
    Gong B; Shin M; Sun J; Jung CH; Bolt EL; van der Oost J; Kim JS
    Proc Natl Acad Sci U S A; 2014 Nov; 111(46):16359-64. PubMed ID: 25368186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The crystal structure of Cpf1 in complex with CRISPR RNA.
    Dong D; Ren K; Qiu X; Zheng J; Guo M; Guan X; Liu H; Li N; Zhang B; Yang D; Ma C; Wang S; Wu D; Ma Y; Fan S; Wang J; Gao N; Huang Z
    Nature; 2016 Apr; 532(7600):522-6. PubMed ID: 27096363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure Reveals a Mechanism of CRISPR-RNA-Guided Nuclease Recruitment and Anti-CRISPR Viral Mimicry.
    Rollins MF; Chowdhury S; Carter J; Golden SM; Miettinen HM; Santiago-Frangos A; Faith D; Lawrence CM; Lander GC; Wiedenheft B
    Mol Cell; 2019 Apr; 74(1):132-142.e5. PubMed ID: 30872121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type III CRISPR-Cas System: Introduction And Its Application for Genetic Manipulations.
    Liu T; Pan S; Li Y; Peng N; She Q
    Curr Issues Mol Biol; 2018; 26():1-14. PubMed ID: 28879852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The CRISPR-Cas Mechanism for Adaptive Immunity and Alternate Bacterial Functions Fuels Diverse Biotechnologies.
    Newsom S; Parameshwaran HP; Martin L; Rajan R
    Front Cell Infect Microbiol; 2020; 10():619763. PubMed ID: 33585286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition Mechanism of an Anti-CRISPR Suppressor AcrIIA4 Targeting SpyCas9.
    Yang H; Patel DJ
    Mol Cell; 2017 Jul; 67(1):117-127.e5. PubMed ID: 28602637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems.
    Chylinski K; Le Rhun A; Charpentier E
    RNA Biol; 2013 May; 10(5):726-37. PubMed ID: 23563642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Revolution Continues: Newly Discovered Systems Expand the CRISPR-Cas Toolkit.
    Murugan K; Babu K; Sundaresan R; Rajan R; Sashital DG
    Mol Cell; 2017 Oct; 68(1):15-25. PubMed ID: 28985502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fanzor is a eukaryotic programmable RNA-guided endonuclease.
    Saito M; Xu P; Faure G; Maguire S; Kannan S; Altae-Tran H; Vo S; Desimone A; Macrae RK; Zhang F
    Nature; 2023 Aug; 620(7974):660-668. PubMed ID: 37380027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct Subcellular Localization of a Type I CRISPR Complex and the Cas3 Nuclease in Bacteria.
    Govindarajan S; Borges A; Karambelkar S; Bondy-Denomy J
    J Bacteriol; 2022 May; 204(5):e0010522. PubMed ID: 35389256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A scoutRNA Is Required for Some Type V CRISPR-Cas Systems.
    Harrington LB; Ma E; Chen JS; Witte IP; Gertz D; Paez-Espino D; Al-Shayeb B; Kyrpides NC; Burstein D; Banfield JF; Doudna JA
    Mol Cell; 2020 Aug; 79(3):416-424.e5. PubMed ID: 32645367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploiting CRISPR/Cas: interference mechanisms and applications.
    Richter H; Randau L; Plagens A
    Int J Mol Sci; 2013 Jul; 14(7):14518-31. PubMed ID: 23857052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR RNA-guided DNA cleavage by reconstituted Type I-A immune effector complexes.
    Majumdar S; Terns MP
    Extremophiles; 2019 Jan; 23(1):19-33. PubMed ID: 30284045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biogenesis pathways of RNA guides in archaeal and bacterial CRISPR-Cas adaptive immunity.
    Charpentier E; Richter H; van der Oost J; White MF
    FEMS Microbiol Rev; 2015 May; 39(3):428-41. PubMed ID: 25994611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.